🇺🇸 FDA

Company profile · Sponsor

CASI

CASI Pharmaceuticals

CASIF · NYSE pharma BEIJING, F4, USA
Pipeline
22
Drugs
1
Patents
2

Quick answer

CASI (CASIF) is a pharma company. headquartered in BEIJING, F4, USA. listed on NYSE. NovaPharmaNews links 22 pipeline programs, 1 drug, and 2 patents to this profile..

Company facts

Ticker CASIF
Exchange NYSE
Company type pharma
Headquarters BEIJING, F4, USA
SEC CIK 0001962738

Pipeline (22)

Search pipeline →

  1. 2-methoxyestradiol

    CASI

    Relapsed Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  2. CID-103

    CASI

    Chronic Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  3. ENMD-2076

    CASI

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  4. ENMD-2076

    CASI

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  5. ENMD-2076

    CASI

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. MKC-1

    CASI

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  7. MKC-1

    CASI

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  8. MKC-1

    CASI

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  9. MKC-1

    CASI

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  10. Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

    CASI

    Carcinoid Tumor

    phase 2 small molecule completed

    1 trial

  11. Panzem NCD

    CASI

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  12. Panzem Nanocrystal Colloidal Dispersion

    CASI

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  13. Panzem Nanocrystal Colloidal Dispersion (NCD)

    CASI

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  14. Panzem® NCD

    CASI

    Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  15. Panzem® NCD

    CASI

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  16. recombinant human Angiostatin protein

    CASI

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  17. CID-103

    CASI

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  18. ENMD-2076

    CASI

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  19. ENMD-2076

    CASI

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  20. ENMD-2076

    CASI

    Relapsed or Refractory Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  21. MKC-1

    CASI

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  22. melphalan hydrochloride for injection

    CASI

    Multiple Myeloma

    approved small molecule active

    2 trials

Drugs (1)

Search drugs →

  1. heparin sodium

    HEPARIN SODIUM

    INJECTION approved

Patents (2)

Search patents →

  1. US 12181485

    Methods of blood screening

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9132138

    Method for the treatment of multiple sclerosis

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is CASI?

CASI (CASIF) is a pharma company. headquartered in BEIJING, F4, USA. listed on NYSE. NovaPharmaNews links 22 pipeline programs, 1 drug, and 2 patents to this profile..

What pipeline programs does CASI sponsor?

We track 22 ClinicalTrials.gov-linked programs for CASI, including 2-methoxyestradiol and 21 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CASI company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.